

Form PTO-1595 (Rev. 07/05) OMB No. 0651-0027 (exp. 6/30/2008)

RECORDATION FORM COVER SHEET PATENTS ONLY

U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office

Atty Docket No.: PP01612.0002

To the Director of Patents and Trademarks: Please record the attached original documents or copy thereof.

<p>1. Name of conveying party(ies):</p> <p>Michael Houghton Mark Selby Xavier Paliard</p> <p>Additional name(s) of conveying party(ies) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>	<p>2. Name and address of receiving party(ies) Name:</p> <p>NOVARTIS VACCINES AND DIAGNOSTICS, INC. 4560 Horton Street Emeryville, CA 94608-2916</p> <p><input type="checkbox"/> Other</p> <p>Additional name(s) & address(es) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>
<p>3. Nature of conveyance:</p> <p><input checked="" type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input type="checkbox"/> Change of Name <input type="checkbox"/> Joint Research Agreement <input type="checkbox"/> Other _____ <input type="checkbox"/> Government Interest Assignment <input type="checkbox"/> Executive Order 9424, Confirmatory License</p> <p>Execution Date(s): 10/18/07, 10/16/07, 10/04/07</p>	

4. Application number(s) or patent number(s):
If this document is being filed together with a new application, the execution date of the application is: _____

A. Patent Application No.(s)

**U.S. Application No.: 09/698,874
Filing Date: October 27, 2000**


Additional number(s) attached Yes No

<p>5. Name and address of party to whom correspondence concerning document should be mailed:</p> <p>NOVARTIS VACCINES AND DIAGNOSTICS, INC. Corporate Intellectual Property - R338 P.O. Box 8097 Emeryville, CA 94662-8097</p>	<p>6. Total number of applications and patents involved 1</p> <p>7. Total fee (37 CFR 3.41)..... \$40.00</p> <p><input type="checkbox"/> Enclosed <input checked="" type="checkbox"/> Authorized to be charged to deposit account</p> <p>8. Deposit account number: 03-1664</p> <p>(Attach duplicate copy of this page if paying by deposit account)</p>
---	---

DO NOT USE THIS SPACE

9. Statement and signature:

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.


Mei Hong (Reg. No. 55,276)  **October 19, 2007**

Name of Person Signing Signature Date

Total number of pages including cover sheet, attachments, and document: **7**

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to: Mail Stop Assignment Recordation Services, Director of the USPTO, P.O. Box 1450, Alexandria, VA 22313-1450

I hereby certify that this paper is being transmitted via facsimile to the Assignment Recordation Services Office of the United States Patent and Trademark Office at facsimile number (571) 273-0140,


Joy M. Marshall

October 19, 2007
Date

CIH \$40.00 031664 09698874

Novartis Docket No. PP01612.0002

ASSIGNMENT

WHEREAS, WE, Michael Houghton, Mark Selby and Xavier Paliard,

hereinafter referred to as **ASSIGNORS**, have invented certain new and useful improvements as described and set forth in the below-identified application for United States Letters Patent:

Title of Invention: **ACTIVATION OF HCV-SPECIFIC T CELLS**
Patent No.: 6,562,346 Date of Patent: May 13, 2003
Application No.: 09/698,874 Filing Date: October 27, 2000

*WHEREAS, Novartis Vaccines and Diagnostics, Inc., 4560 Horton Street, Emeryville, California 94608-2916, a corporation of the State of Delaware, hereinafter referred to as **ASSIGNEE**, is desirous of acquiring the entire right, title and interest in the above invention and application and in any Letters Patent which may be granted on the same;*

*NOW, THEREFORE, TO ALL WHOM IT MAY CONCERN: Be it known that, for and in consideration of the sum of One Dollar (\$1.00) lawful money paid to **ASSIGNORS** by **ASSIGNEE**, receipt of which is hereby acknowledged, **ASSIGNORS** have sold, assigned and transferred, and by these presents do sell, assign and transfer unto said **ASSIGNEE**, and **ASSIGNEE'S** successors and assigns, all right, title and interest in and to the said invention, said application for United States Letters Patent, and any Letters Patent which may hereafter be granted on the same in the United States and all countries throughout the world including any divisions, renewals, continuations in whole or in part, substitutions, conversions (including conversions claiming priority under 35 U.S.C. § 119(e)), reissues, prolongations or extensions thereof, the said interest to be held and enjoyed by said **ASSIGNEE** as fully and exclusively as it would have been held and enjoyed by said **ASSIGNORS** had this assignment and transfer not been made, to the full end and term of any Letters Patent.*

Novartis Docket No. PP0.612.0002

ASSIGNORS further agree that they will, without charge to said **ASSIGNEE**, but at **ASSIGNEE'S** expense, cooperate with **ASSIGNEE** in the prosecution of said application and/or applications, execute, verify, acknowledge and deliver all such further papers, including applications for Letters Patent and for the reissue thereof, and instruments of assignment and transfer thereof, and will perform such other acts as **ASSIGNEE** lawfully may request, to obtain or maintain Letters Patent for said invention and improvement in any and all countries, and to vest title thereto in said **ASSIGNEE**, or **ASSIGNEE'S** successors and assigns.

IN TESTIMONY WHEREOF, ASSIGNORS have hereunto signed their names to this assignment on the dates indicated below.

DATE 10/18/07

M. Houghton
Michael Houghton

Davis C. Myers
Print Witness Name

D. C. Myers
Witness Signature

DATE _____

Mark Selby

Print Witness Name

Witness Signature

DATE _____

Xavier Paliard

Print Witness Name

Witness Signature

Novartis Docket No. PP01612.0002

ASSIGNMENT

WHEREAS, WE, Michael Houghton, Mark Selby and Xavier Paliard,

hereinafter referred to as **ASSIGNORS**, have invented certain new and useful improvements as described and set forth in the below-identified application for United States Letters Patent:

Title of Invention: **ACTIVATION OF HCV-SPECIFIC T CELLS**

Patent No.: 6,562,346 Date of Patent: May 13, 2003

Application No.: 09/698,874 Filing Date: October 27, 2000

WHEREAS, Novartis Vaccines and Diagnostics, Inc., 4560 Horton Street, Emeryville, California 94608-2916, a corporation of the State of Delaware, hereinafter referred to as **ASSIGNEE**, is desirous of acquiring the entire right, title and interest in the above invention and application and in any Letters Patent which may be granted on the same;

NOW, THEREFORE, TO ALL WHOM IT MAY CONCERN: Be it known that, for and in consideration of the sum of One Dollar (\$1.00) lawful money paid to **ASSIGNORS** by **ASSIGNEE**, receipt of which is hereby acknowledged, **ASSIGNORS** have sold, assigned and transferred, and by these presents do sell, assign and transfer unto said **ASSIGNEE**, and **ASSIGNEE'S** successors and assigns, all right, title and interest in and to the said invention, said application for United States Letters Patent, and any Letters Patent which may hereafter be granted on the same in the United States and all countries throughout the world including any divisions, renewals, continuations in whole or in part, substitutions, conversions (including conversions claiming priority under 35 U.S.C. § 119(e)), reissues, prolongations or extensions thereof, the said interest to be held and enjoyed by said **ASSIGNEE** as fully and exclusively as it would have been held and enjoyed by said **ASSIGNORS** had this assignment and transfer not been made, to the full end and term of any Letters Patent.

Novartis Docket No. PP01612.0002

ASSIGNORS further agree that they will, without charge to said **ASSIGNEE**, but at **ASSIGNEE'S** expense, cooperate with **ASSIGNEE** in the prosecution of said application and/or applications, execute, verify, acknowledge and deliver all such further papers, including applications for Letters Patent and for the reissue thereof, and instruments of assignment and transfer thereof, and will perform such other acts as **ASSIGNEE** lawfully may request, to obtain or maintain Letters Patent for said invention and improvement in any and all countries, and to vest title thereto in said **ASSIGNEE**, or **ASSIGNEE'S** successors and assigns.

IN TESTIMONY WHEREOF, ASSIGNORS have hereunto signed their names to this assignment on the dates indicated below.

DATE _____

Michael Houghton

Print Witness Name

Witness Signature

DATE 10/16/2007

Mark Selby

Daniel Rohrer
Print Witness Name

Witness Signature

DATE _____

Xavier Paliard

Print Witness Name

Witness Signature

Novartis Docket No. PP01612.0002

ASSIGNMENT

WHEREAS, WE, Michael Houghton, Mark Selby and Xavier Paliard,

hereinafter referred to as **ASSIGNORS**, have invented certain new and useful improvements as described and set forth in the below-identified application for United States Letters Patent:

Title of Invention: **ACTIVATION OF HCV-SPECIFIC T CELLS**

Patent No.: 6,562,346

Date of Patent: May 13, 2003

Application No.: 09/698,874

Filing Date: October 27, 2000

WHEREAS, Novartis Vaccines and Diagnostics, Inc., 4560 Horton Street, Emeryville, California 94608-2916, a corporation of the State of Delaware, hereinafter referred to as **ASSIGNEE**, is desirous of acquiring the entire right, title and interest in the above invention and application and in any Letters Patent which may be granted on the same;

NOW, THEREFORE, TO ALL WHOM IT MAY CONCERN: Be it known that, for and in consideration of the sum of One Dollar (\$1.00) lawful money paid to **ASSIGNORS** by **ASSIGNEE**, receipt of which is hereby acknowledged, **ASSIGNORS** have sold, assigned and transferred, and by these presents do sell, assign and transfer unto said **ASSIGNEE**, and **ASSIGNEE'S** successors and assigns, all right, title and interest in and to the said invention, said application for United States Letters Patent, and any Letters Patent which may hereafter be granted on the same in the United States and all countries throughout the world including any divisions, renewals, continuations in whole or in part, substitutions, conversions (including conversions claiming priority under 35 U.S.C. § 119(e)), reissues, prolongations or extensions thereof, the said interest to be held and enjoyed by said **ASSIGNEE** as fully and exclusively as it would have been held and enjoyed by said **ASSIGNORS** had this assignment and transfer not been made, to the full end and term of any Letters Patent.

Novartis Docket No. PP01612.0002

ASSIGNORS further agree that they will, without charge to said **ASSIGNEE**, but at **ASSIGNEE'S** expense, cooperate with **ASSIGNEE** in the prosecution of said application and/or applications, execute, verify, acknowledge and deliver all such further papers, including applications for Letters Patent and for the reissue thereof, and instruments of assignment and transfer thereof, and will perform such other acts as **ASSIGNEE** lawfully may request, to obtain or maintain Letters Patent for said invention and improvement in any and all countries, and to vest title thereto in said **ASSIGNEE**, or **ASSIGNEE'S** successors and assigns.

IN TESTIMONY WHEREOF, ASSIGNORS have hereunto signed their names to this assignment on the dates indicated below.

DATE _____

Michael Houghton

Print Witness Name

Witness Signature

DATE _____

Mark Selby

Print Witness Name

Witness Signature

DATE 04 OCT 2007



Xavier Pallard

STACK WELCH

Print Witness Name



Witness Signature